Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
1.
Bioorg Med Chem Lett ; 94: 129454, 2023 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-37591316

RESUMO

Activation of the glucagon-like peptide-1 (GLP-1) receptor stimulates insulin release, lowers plasma glucose levels, delays gastric emptying, increases satiety, suppresses food intake, and affords weight loss in humans. These beneficial attributes have made peptide-based agonists valuable tools for the treatment of type 2 diabetes mellitus and obesity. However, efficient, and consistent delivery of peptide agents generally requires subcutaneous injection, which can reduce patient utilization. Traditional orally absorbed small molecules for this target may offer improved patient compliance as well as the opportunity for co-formulation with other oral therapeutics. Herein, we describe an SAR investigation leading to small-molecule GLP-1 receptor agonists that represent a series that parallels the recently reported clinical candidate danuglipron. In the event, identification of a benzyloxypyrimidine lead, using a sensitized high-throughput GLP-1 agonist assay, was followed by optimization of the SAR using substituent modifications analogous to those discovered in the danuglipron series. A new series of 6-azaspiro[2.5]octane molecules was optimized into potent GLP-1 agonists. Information gleaned from cryogenic electron microscope structures was used to rationalize the SAR of the optimized compounds.


Assuntos
Diabetes Mellitus Tipo 2 , Receptor do Peptídeo Semelhante ao Glucagon 1 , Humanos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Peptídeo 1 Semelhante ao Glucagon , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Ensaios de Triagem em Larga Escala , Hipoglicemiantes/farmacologia , Octanos/química , Octanos/farmacologia , Compostos de Espiro/química , Compostos de Espiro/farmacologia
2.
Bioorg Med Chem Lett ; 92: 129394, 2023 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-37379958

RESUMO

Our previous work on the optimization of a new class of small molecule PCSK9 mRNA translation inhibitors focused on empirical optimization of the amide tail region of the lead PF-06446846 (1). This work resulted in compound 3 that showed an improved safety profile. We hypothesized that this improvement was related to diminished binding of 3 to non-translating ribosomes and an apparent improvement in transcript selectivity. Herein, we describe our efforts to further optimize this series of inhibitors through modulation of the heterocyclic head group and the amine fragment. Some of the effort was guided by an emerging cryo electron microscopy structure of the binding mode of 1 in the ribosome. These efforts led to the identification of 15 that was deemed suitable for evaluation in a humanized PCSK9 mouse model and a rat toxicology study. Compound 15 demonstrated a dose dependent reduction of plasma PCSK9 levels. The rat toxicological profile was not improved over that of 1, which precluded 15 from further consideration as a clinical candidate.

3.
Bioorg Med Chem Lett ; 93: 129433, 2023 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-37557923

RESUMO

The α7 nicotinic acetylcholine receptor is a calcium permeable, ligand-gated ion channel that modulates synaptic transmission in the hippocampus, thalamus, and cerebral cortex. Previously disclosed work described PNU-120596 that acts as a powerful positive allosteric modulator of the α7 nicotinic acetylcholine receptor. The initial structure-activity relationships around PNU-120596 were gleaned from screening a large thiazole library. Independent systematic examination of the aryl and heteroaryl groups resulted in compounds with enhanced potency and improved physico-chemical properties culminating in the identification of 16 (PHA-758454). In the presence of acetylcholine, 16 enhanced evoked currents in rat hippocampal neurons. In a rat model of impaired sensory gating, treatment with 16 led to a reversal of the gating deficit in a dose-dependent manner. These results demonstrate that aryl heteroaryl ureas, like compound 16, may be useful tools for continued exploration of the unique biology of the α7 nicotinic acetylcholine receptor.


Assuntos
Receptores Nicotínicos , Receptor Nicotínico de Acetilcolina alfa7 , Ratos , Animais , Hipocampo , Compostos de Fenilureia/química , Isoxazóis/farmacologia , Isoxazóis/química , Regulação Alostérica
5.
J Org Chem ; 86(10): 7189-7202, 2021 05 21.
Artigo em Inglês | MEDLINE | ID: mdl-33974415

RESUMO

Non-enzymatic dynamic kinetic resolution (DKR) of secondary alcohols by enantioselective acylation using an isothiourea-derived HyperBTM catalyst and racemization of slowly reacting alcohol by Bäckvall's ruthenium complex is reported. The DKR approach features high enantioselectivities (up to 99:1), employs easy-to-handle crystalline 4-nitrophenyl isobutyrate as the acylating reagent, and proceeds at room temperature and under an ambient atmosphere. The stereoinduction model featuring cation-π system interactions between the acylated HyperBTM catalyst and π electrons of an alcohol aryl subunit has been elaborated by DFT calculations.


Assuntos
Rutênio , Álcoois , Catálise , Cinética , Estereoisomerismo
6.
PLoS Biol ; 15(3): e2001882, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28323820

RESUMO

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel. We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing. Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation. The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small molecules to specifically block translation of individual transcripts.


Assuntos
Biossíntese de Proteínas/efeitos dos fármacos , Ribossomos/efeitos dos fármacos , Animais , Linhagem Celular , Sistema Livre de Células , Colesterol/sangue , Escherichia coli/genética , Células HeLa , Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia , Humanos , Masculino , Espectrometria de Massas , Terapia de Alvo Molecular , Pró-Proteína Convertase 9/sangue , Pró-Proteína Convertase 9/genética , Biossíntese de Proteínas/fisiologia , Coelhos , Ratos , Ratos Sprague-Dawley , Ribossomos/metabolismo , Ribossomos/fisiologia
7.
Angew Chem Int Ed Engl ; 59(31): 12998-13003, 2020 07 27.
Artigo em Inglês | MEDLINE | ID: mdl-32285542

RESUMO

Preparative reactions that occur efficiently under dilute, buffered, aqueous conditions in the presence of biomolecules find application in ligation, peptide synthesis, and polynucleotide synthesis and sequencing. However, the identification of functional groups or reagents that are mutually reactive with one another, but unreactive with biopolymers and water, is challenging. Shown here are cobalt catalysts that react with alkenes under dilute, aqueous, buffered conditions and promote efficient cycloisomerization and formal Friedel-Crafts reactions. The constraining conditions of bioorthogonal chemistry are beneficial for reaction efficiency as superior conversion at low catalyst concentration is obtained and competent rates in dilute conditions are maintained. Efficiency at high dilution in the presence of buffer and nucleobases suggests that these reaction conditions may find broad application.


Assuntos
Alcenos/química , Água/química , Catálise , Cobalto/química , Complexos de Coordenação/química , Ciclização , Compostos Heterocíclicos com 2 Anéis/síntese química , Compostos Heterocíclicos com 3 Anéis/síntese química , Isomerismo
8.
Angew Chem Int Ed Engl ; 59(19): 7377-7383, 2020 05 04.
Artigo em Inglês | MEDLINE | ID: mdl-32050046

RESUMO

DNA encoded libraries (DEL) have shown promise as a valuable technology for democratizing the hit discovery process. Although DEL provides relatively inexpensive access to libraries of unprecedented size, their production has been hampered by the idiosyncratic needs of the encoding DNA tag relegating DEL compatible chemistry to dilute aqueous environments. Recently reversible adsorption to solid support (RASS) has been demonstrated as a promising method to expand DEL reactivity using standard organic synthesis protocols. Here we demonstrate a suite of on-DNA chemistries to incorporate medicinally relevant and C-S, C-P and N-S linkages into DELs, which are underrepresented in the canonical methods.


Assuntos
DNA/síntese química , Adsorção , Técnicas de Química Sintética , Técnicas de Química Combinatória , Descoberta de Drogas , Indicadores e Reagentes , Bibliotecas de Moléculas Pequenas , Solubilidade , Sulfonas/química , Sulfóxidos/química
9.
J Am Chem Soc ; 141(25): 9998-10006, 2019 06 26.
Artigo em Inglês | MEDLINE | ID: mdl-31136164

RESUMO

DNA Encoded Libraries have proven immensely powerful tools for lead identification. The ability to screen billions of compounds at once has spurred increasing interest in DEL development and utilization. Although DEL provides access to libraries of unprecedented size and diversity, the idiosyncratic and hydrophilic nature of the DNA tag severely limits the scope of applicable chemistries. It is known that biomacromolecules can be reversibly, noncovalently adsorbed and eluted from solid supports, and this phenomenon has been utilized to perform synthetic modification of biomolecules in a strategy we have described as reversible adsorption to solid support (RASS). Herein, we present the adaptation of RASS for a DEL setting, which allows reactions to be performed in organic solvents at near anhydrous conditions opening previously inaccessible chemical reactivities to DEL. The RASS approach enabled the rapid development of C(sp2)-C(sp3) decarboxylative cross-couplings with broad substrate scope, an electrochemical amination (the first electrochemical synthetic transformation performed in a DEL context), and improved reductive amination conditions. The utility of these reactions was demonstrated through a DEL-rehearsal in which all newly developed chemistries were orchestrated to afford a compound rich in diverse skeletal linkages. We believe that RASS will offer expedient access to new DEL reactivities, expanded chemical space, and ultimately more drug-like libraries.


Assuntos
Compostos de Anilina/síntese química , Técnicas de Química Combinatória/métodos , DNA/química , Piperidinas/síntese química , Compostos de Amônio Quaternário/química , Estudo de Prova de Conceito
10.
Bioorg Med Chem Lett ; 28(23-24): 3685-3688, 2018 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-30482620

RESUMO

A series of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides were identified as small molecule PCSK9 mRNA translation inhibitors. Analogues from this new chemical series, such as 4d and 4g, exhibited improved PCSK9 potency, ADME properties, and in vitro safety profiles when compared to earlier lead structures.


Assuntos
Amidas/química , Inibidores de PCSK9 , Piperidinas/química , Inibidores de Proteases/química , Amidas/metabolismo , Amidas/farmacologia , Animais , Permeabilidade da Membrana Celular/efeitos dos fármacos , Cristalografia por Raios X , Cães , Humanos , Concentração Inibidora 50 , Células Madin Darby de Rim Canino , Conformação Molecular , Pró-Proteína Convertase 9/metabolismo , Inibidores de Proteases/metabolismo , Inibidores de Proteases/farmacologia , Relação Estrutura-Atividade
11.
J Org Chem ; 82(2): 869-886, 2017 01 20.
Artigo em Inglês | MEDLINE | ID: mdl-28060519

RESUMO

A new catalyst for the dynamic kinetic resolution of azole hemiaminals has been developed using late-stage structural modifications of the tert-leucinol-derived chiral subunit of DMAP species.

12.
Angew Chem Int Ed Engl ; 56(51): 16218-16222, 2017 12 18.
Artigo em Inglês | MEDLINE | ID: mdl-29073340

RESUMO

Targeting of the human ribosome is an unprecedented therapeutic modality with a genome-wide selectivity challenge. A liver-targeted drug candidate is described that inhibits ribosomal synthesis of PCSK9, a lipid regulator considered undruggable by small molecules. Key to the concept was the identification of pharmacologically active zwitterions designed to be retained in the liver. Oral delivery of the poorly permeable zwitterions was achieved by prodrugs susceptible to cleavage by carboxylesterase 1. The synthesis of select tetrazole prodrugs was crucial. A cell-free in vitro translation assay containing human cell lysate and purified target mRNA fused to a reporter was used to identify active zwitterions. In vivo PCSK9 lowering by oral dosing of the candidate prodrug and quantification of the drug fraction delivered to the liver utilizing an oral positron emission tomography 18 F-isotopologue validated our liver-targeting approach.


Assuntos
Fígado/efeitos dos fármacos , Inibidores de PCSK9 , Pró-Proteína Convertase 9/biossíntese , Bibliotecas de Moléculas Pequenas/farmacologia , Relação Dose-Resposta a Droga , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Fígado/enzimologia , Fígado/metabolismo , Estrutura Molecular , Pró-Proteína Convertase 9/metabolismo , Bibliotecas de Moléculas Pequenas/química , Relação Estrutura-Atividade
13.
J Am Chem Soc ; 138(14): 4818-23, 2016 Apr 13.
Artigo em Inglês | MEDLINE | ID: mdl-27003237

RESUMO

We report a modular three-component dynamic kinetic resolution (DKR) that affords enantiomerically enriched hemiaminal esters derived from azoles and aldehydes. The novel and scalable reaction can be used to synthesize valuable substituted azoles in a regioselective manner by capping (e.g., acylation) of the equilibrating azole-aldehyde adduct. With the use of a prolinol-derived DMAP catalyst as the chiral Lewis base, the products can be obtained in high chemical yield and with high enantiomeric excess. The DKR was performed on a multikilogram scale to produce a tetrazole prodrug fragment for a leading clinical candidate that posed formidable synthesis challenges.


Assuntos
Azóis/síntese química , Ésteres/síntese química , Bases de Lewis/química , Aldeídos/química , Alcanossulfonatos/síntese química , Alcanossulfonatos/química , Azóis/química , Catálise , Ésteres/química , Cinética , Estereoisomerismo , Tetrazóis
15.
Bioorg Med Chem Lett ; 23(23): 6239-42, 2013 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-24157365

RESUMO

Hit-to-lead medicinal chemistry efforts are described starting from a screening hit 1, leading to a new class of aryl sulfonamide-based MR antagonist, exemplified by 17, that possesses favourable MR binding affinity, selectivity profile against closely related NHRs, physicochemical properties and metabolic stability.


Assuntos
Antagonistas de Receptores de Mineralocorticoides/química , Antagonistas de Receptores de Mineralocorticoides/farmacologia , Sulfonamidas/química , Sulfonamidas/farmacologia , Humanos , Antagonistas de Receptores de Mineralocorticoides/síntese química , Modelos Moleculares , Relação Estrutura-Atividade , Sulfonamidas/síntese química
16.
Bioorg Med Chem Lett ; 23(5): 1407-11, 2013 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-23337601

RESUMO

Optimization of a high-throughput screening hit led to the discovery of a new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as highly potent agonists of TGR5. This novel chemotype was rapidly developed through iterative combinatorial library synthesis. It was determined that in vitro agonist potency correlated with functional activity data from human peripheral blood monocytes.


Assuntos
Amidas/síntese química , Amidas/farmacologia , Pirazóis/síntese química , Pirazóis/farmacologia , Receptores Acoplados a Proteínas G/agonistas , Amidas/química , Técnicas de Química Combinatória , Humanos , Pirazóis/química , Relação Estrutura-Atividade
17.
Angew Chem Int Ed Engl ; 52(40): 10607-10, 2013 Sep 27.
Artigo em Inglês | MEDLINE | ID: mdl-23956102

RESUMO

Two regioselective and complementary hydroarylation reactions of an unsymmetrical cyclic olefin have been developed. The products can be transformed in one step into constrained γ-amino acids. Regioselective arylation of Vince lactam is controlled by the choice of phosphine ligand enantiomer and the substituent on the amide nitrogen atom. The method was extended to a general regiodivergent parallel kinetic resolution of the racemic lactam.


Assuntos
Lactamas/química , Compostos Organometálicos/química , Catálise , Cinética , Modelos Moleculares , Estrutura Molecular , Estereoisomerismo
18.
Drug Metab Dispos ; 40(11): 2143-61, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22896728

RESUMO

The disposition of 3,3-difluoropyrrolidin-1-yl{(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone (PF-00734200), a dipeptidyl peptidase IV inhibitor that progressed to phase 3 for the treatment of type 2 diabetes, was examined in rats, dogs, and humans after oral administration of a single dose of [(14)C]PF-00734200. Mean recoveries of administered radioactivity were 97.1, 92.2, and 87.2% in rats, dogs, and humans, respectively. The majority of radioactive dose was detected in the urine of dogs and humans and in the feces of rats. Absorption of PF-00734200 was rapid in all species, with maximal plasma concentrations of radioactivity achieved within 1 h after the dose. Circulating radioactivity was primarily composed of the parent drug (79.9, 80.2, and 94.4% in rat, dog, and human, respectively). The major route of metabolism was due to hydroxylation at the 5' position of the pyrimidine ring (M5) in all species. In vitro experiments with recombinant cytochrome P450 isoforms suggested that the formation of M5 was catalyzed both by CYP2D6 and CYP3A4. Molecular docking simulations showed that the 5' position of the pyrimidine moiety of PF-00734200 can access the heme iron-oxo of both CYP3A4 and CYP2D6 in an energetically favored orientation. Other metabolic pathways included amide hydrolysis (M2), N-dealkylation at the piperazine nitrogen (M3) and an unusual metabolite resulting from scission of the pyrimidine ring (M1). Phase II metabolic pathways included the following: carbamoyl glucuronidation (M9), glucosidation (M15) on the pyrrolidine nitrogen, and conjugation with creatinine to form an unusual metabolite/metabonate (M16). The data from these studies suggest that PF-00734200 is eliminated by both metabolism and renal clearance.


Assuntos
Inibidores da Dipeptidil Peptidase IV/metabolismo , Inibidores da Dipeptidil Peptidase IV/farmacocinética , Dipeptidil Peptidases e Tripeptidil Peptidases/antagonistas & inibidores , Pirimidinas/metabolismo , Pirrolidinas/metabolismo , Amidas/metabolismo , Animais , Citocromo P-450 CYP2D6/metabolismo , Citocromo P-450 CYP3A/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/enzimologia , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/urina , Inibidores da Dipeptidil Peptidase IV/urina , Dipeptidil Peptidases e Tripeptidil Peptidases/metabolismo , Cães , Fezes/química , Feminino , Humanos , Hidrólise/efeitos dos fármacos , Hidroxilação/efeitos dos fármacos , Masculino , Desintoxicação Metabólica Fase II , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Simulação de Acoplamento Molecular/métodos , Piperazina , Piperazinas/metabolismo , Pirimidinas/farmacocinética , Pirrolidinas/farmacocinética , Ratos , Ratos Sprague-Dawley
19.
J Med Chem ; 65(12): 8208-8226, 2022 06 23.
Artigo em Inglês | MEDLINE | ID: mdl-35647711

RESUMO

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.


Assuntos
Receptor do Peptídeo Semelhante ao Glucagon 1 , Hipoglicemiantes , Animais , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Humanos , Hipoglicemiantes/farmacologia , Peptídeos/química
20.
J Transl Med ; 9: 180, 2011 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-22017794

RESUMO

BACKGROUND: Accumulating evidence supports the role of the mineralocorticoid receptor (MR) in the pathogenesis of diabetic nephropathy. These findings have generated renewed interest in novel MR antagonists with improved selectivity against other nuclear hormone receptors and a potentially reduced risk of hyperkalemia. Characterization of novel MR antagonists warrants establishing translatable biomarkers of activity at the MR receptor. We assessed the translatability of urinary sodium to potassium ratio (Na+/K+) and plasma aldosterone as biomarkers of MR antagonism using eplerenone (Inspra®), a commercially available MR antagonist. Further we utilized these biomarkers to demonstrate antagonism of MR by PF-03882845, a novel compound. METHODS: The effect of eplerenone and PF-03882845 on urinary Na+/K+ and plasma aldosterone were characterized in Sprague-Dawley rats and spontaneously hypertensive rats (SHR). Additionally, the effect of eplerenone on these biomarkers was determined in healthy volunteers. Drug exposure-response data were modeled to evaluate the translatability of these biomarkers from rats to humans. RESULTS: In Sprague-Dawley rats, eplerenone elicited a rapid effect on urinary Na+/K+ yielding an EC50 that was within 5-fold of the functional in vitro IC50. More importantly, the effect of eplerenone on urinary Na+/K+ in healthy volunteers yielded an EC50 that was within 2-fold of the EC50 generated in Sprague-Dawley rats. Similarly, the potency of PF-03882845 in elevating urinary Na+/K+ in Sprague-Dawley rats was within 3-fold of its in vitro functional potency. The effect of MR antagonism on urinary Na+/K+ was not sustained chronically; thus we studied the effect of the compounds on plasma aldosterone following chronic dosing in SHR. Modeling of drug exposure-response data for both eplerenone and PF-03882845 yielded EC50 values that were within 2-fold of that estimated from modeling of drug exposure with changes in urinary sodium and potassium excretion. Importantly, similar unbound concentrations of eplerenone in humans and SHR rats yielded the same magnitude of elevations in aldosterone, indicating a good translatability from rat to human. CONCLUSIONS: Urinary Na+/K+ and plasma aldosterone appear to be translatable biomarkers of MR antagonism following administration of single or multiple doses of compound, respectively. TRIAL REGISTRATION: For clinical study reference EE3-96-02-004, this study was completed in 1996 and falls out scope for disclosure requirements. Clinical study reference A6141115: http://clinicaltrials.gov, http://NIHclinicaltrails.gov; NCTID: NCT00990223.


Assuntos
Aldosterona/sangue , Antagonistas de Receptores de Mineralocorticoides , Potássio/urina , Sódio/urina , Pesquisa Translacional Biomédica , Adulto , Animais , Área Sob a Curva , Biomarcadores/sangue , Biomarcadores/urina , Linhagem Celular Tumoral , Eplerenona , Humanos , Masculino , Ratos , Ratos Sprague-Dawley , Receptores de Mineralocorticoides/metabolismo , Espironolactona/administração & dosagem , Espironolactona/análogos & derivados , Espironolactona/farmacologia , Fatores de Tempo , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA